Id
|
Protein
|
PTM type
|
Site
|
Species
|
Disease
|
Celline
|
Drug
|
Regulatory
|
Score
|
Ref.
|
acc0251 |
AKT |
phosphorylation |
Ser473 |
human |
Ovarian Cancer |
A2780 |
arsenic trioxide (ATO) |
Unresolved |
4.0 |
21655183
|
acc0252 |
AKT |
phosphorylation |
Ser473 |
human |
Ovarian Cancer |
COC1 |
arsenic trioxide (ATO) |
Unresolved |
4.0 |
21655183
|
acc0253 |
AKT |
phosphorylation |
Ser473 |
human |
Ovarian Cancer |
COC1/CP |
arsenic trioxide (ATO) |
Unresolved |
4.0 |
21655183
|
acc0254 |
AKT |
phosphorylation |
Ser473 |
human |
Ovarian Cancer |
A2780/CP |
arsenic trioxide (ATO) |
Unresolved |
4.0 |
21655183
|
acc0255 |
AKT |
phosphorylation |
Ser473 |
human |
Ovarian Cancer |
OVCAR-3 |
arsenic trioxide (ATO) |
Unresolved |
4.0 |
21655183
|
acc0256 |
p65 |
phosphorylation |
Ser536 |
hamster |
Oral Cancer |
|
Andrographolide |
Unresolved |
4.0 |
21841043
|
acc0257 |
IkappaBalpha |
phosphorylation |
Ser32 |
hamster |
Oral Cancer |
|
Andrographolide |
Unresolved |
4.0 |
21841043
|
acc0258 |
IkappaBalpha |
phosphorylation |
Ser36 |
hamster |
Oral Cancer |
|
Andrographolide |
Unresolved |
4.0 |
21841043
|
acc0259 |
VEGFR2 |
phosphorylation |
Tyr1175 |
human |
Hepatocellular Carcinoma |
KYN-2 |
Vandetanib |
Unresolved |
4.0 |
22611027
|
acc0260 |
VEGFR2 |
phosphorylation |
Tyr1175 |
human |
Hepatocellular Carcinoma |
HAK1-B |
Vandetanib |
Unresolved |
4.0 |
22611027
|
acc0261 |
VEGFR2 |
phosphorylation |
Tyr1175 |
human |
Hepatocellular Carcinoma |
HuH-7 |
Vandetanib |
Unresolved |
4.0 |
22611027
|
acc0262 |
EGFR |
phosphorylation |
Tyr1173 |
human |
Hepatocellular Carcinoma |
KYN-2 |
Vandetanib |
Unresolved |
4.0 |
22611027
|
acc0263 |
EGFR |
phosphorylation |
Tyr1173 |
human |
Hepatocellular Carcinoma |
HAK1-B |
Vandetanib |
Unresolved |
4.0 |
22611027
|
acc0264 |
EGFR |
phosphorylation |
Tyr1173 |
human |
Hepatocellular Carcinoma |
HuH-7 |
Vandetanib |
Unresolved |
4.0 |
22611027
|
acc0265 |
MET |
phosphorylation |
Tyr1234 |
human |
Ovarian Cancer |
58As9 |
Crizotinib |
Unresolved |
4.0 |
22729845
|
acc0266 |
MET |
phosphorylation |
Tyr1234 |
human |
Gastric Cancer |
SNU5 |
Crizotinib |
Unresolved |
4.0 |
22729845
|
acc0267 |
MET |
phosphorylation |
Tyr1234 |
human |
Hepatocellular Carcinoma |
HSC58 |
Crizotinib |
Unresolved |
4.0 |
22729845
|
acc0268 |
MET |
phosphorylation |
Tyr1234 |
human |
Ovarian Cancer |
58As1 |
Crizotinib |
Unresolved |
4.0 |
22729845
|
acc0269 |
MET |
phosphorylation |
Tyr1235 |
human |
Ovarian Cancer |
58As9 |
Crizotinib |
Unresolved |
4.0 |
22729845
|
acc0270 |
MET |
phosphorylation |
Tyr1235 |
human |
Gastric Cancer |
SNU5 |
Crizotinib |
Unresolved |
4.0 |
22729845
|
acc0271 |
MET |
phosphorylation |
Tyr1235 |
human |
Hepatocellular Carcinoma |
HSC58 |
Crizotinib |
Unresolved |
4.0 |
22729845
|
acc0272 |
MET |
phosphorylation |
Tyr1235 |
human |
Ovarian Cancer |
58As1 |
Crizotinib |
Unresolved |
4.0 |
22729845
|
acc0273 |
ERK1 |
phosphorylation |
Thr202 |
human |
Colorectal Cancer |
HT29 |
PMA |
Unresolved |
4.0 |
22812190
|
acc0274 |
ERK1 |
phosphorylation |
Tyr204 |
human |
Colorectal Cancer |
HT29 |
PMA |
Unresolved |
4.0 |
22812190
|
acc0275 |
ERK2 |
phosphorylation |
Thr185 |
human |
Colorectal Cancer |
HT29 |
PMA |
Unresolved |
4.0 |
22812190
|
acc0276 |
ERK2 |
phosphorylation |
Tyr187 |
human |
Colorectal Cancer |
HT29 |
PMA |
Unresolved |
4.0 |
22812190
|
acc0277 |
ITGB4 |
phosphorylation |
Ser1356 |
human |
Skin Cancer |
A431 |
Cyclosporine A |
Unresolved |
4.0 |
22865863
|
acc0278 |
ITGB4 |
phosphorylation |
Ser1356 |
human |
Tongue Cancer |
SCC25 |
Cyclosporine A |
Unresolved |
4.0 |
22865863
|
acc0279 |
ITGB4 |
phosphorylation |
Ser1356 |
human |
Skin Cancer |
Colo16 |
Cyclosporine A |
Unresolved |
4.0 |
22865863
|
acc0280 |
Src |
phosphorylation |
Tyr416 |
human |
Sarcoma |
CME-1 |
Dasatinib |
Unresolved |
4.0 |
23580575
|
acc0281 |
Src |
phosphorylation |
Tyr416 |
human |
Sarcoma |
1273/99 |
Dasatinib |
Unresolved |
4.0 |
23580575
|
acc0282 |
FAK |
phosphorylation |
Tyr576 |
human |
Sarcoma |
FUJI |
Dasatinib |
Unresolved |
4.0 |
23580575
|
acc0283 |
FAK |
phosphorylation |
Tyr576 |
human |
Sarcoma |
SYO-1 |
Dasatinib |
Unresolved |
4.0 |
23580575
|
acc0284 |
FAK |
phosphorylation |
Tyr577 |
human |
Sarcoma |
CME-1 |
Dasatinib |
Unresolved |
4.0 |
23580575
|
acc0285 |
FAK |
phosphorylation |
Tyr577 |
human |
Sarcoma |
1273/99 |
Dasatinib |
Unresolved |
4.0 |
23580575
|
acc0286 |
FAK |
phosphorylation |
Tyr577 |
human |
Sarcoma |
FUJI |
Dasatinib |
Unresolved |
4.0 |
23580575
|
acc0287 |
FAK |
phosphorylation |
Tyr577 |
human |
Sarcoma |
SYO-1 |
Dasatinib |
Unresolved |
4.0 |
23580575
|
acc0288 |
STAT3 |
phosphorylation |
Tyr705 |
human |
Sarcoma |
CME-1 |
Dasatinib |
Unresolved |
4.0 |
23580575
|
acc0289 |
STAT3 |
phosphorylation |
Tyr705 |
human |
Sarcoma |
1273/99 |
Dasatinib |
Unresolved |
4.0 |
23580575
|
acc0290 |
STAT3 |
phosphorylation |
Tyr705 |
human |
Sarcoma |
FUJI |
Dasatinib |
Unresolved |
4.0 |
23580575
|
acc0291 |
STAT3 |
phosphorylation |
Tyr705 |
human |
Sarcoma |
SYO-1 |
Dasatinib |
Unresolved |
4.0 |
23580575
|
acc0292 |
Src |
phosphorylation |
Tyr416 |
human |
Sarcoma |
FUJI |
Dasatinib |
Unresolved |
4.0 |
23580575
|
acc0293 |
IGF-IR |
phosphorylation |
Tyr1131 |
human |
Sarcoma |
CME-1 |
Dasatinib |
Unresolved |
4.0 |
23580575
|
acc0294 |
IGF-IR |
phosphorylation |
Tyr1131 |
human |
Sarcoma |
1273/99 |
Dasatinib |
Unresolved |
4.0 |
23580575
|
acc0295 |
IGF-IR |
phosphorylation |
Tyr1131 |
human |
Sarcoma |
FUJI |
Dasatinib |
Unresolved |
4.0 |
23580575
|
acc0296 |
IGF-IR |
phosphorylation |
Tyr1131 |
human |
Sarcoma |
SYO-1 |
Dasatinib |
Unresolved |
4.0 |
23580575
|
acc0297 |
Src |
phosphorylation |
Tyr416 |
human |
Sarcoma |
SYO-1 |
Dasatinib |
Unresolved |
4.0 |
23580575
|
acc0298 |
AKT |
phosphorylation |
Ser473 |
human |
Sarcoma |
CME-1 |
Dasatinib |
Unresolved |
4.0 |
23580575
|
acc0299 |
AKT |
phosphorylation |
Ser473 |
human |
Sarcoma |
1273/99 |
Dasatinib |
Unresolved |
4.0 |
23580575
|
acc0300 |
AKT |
phosphorylation |
Ser473 |
human |
Sarcoma |
FUJI |
Dasatinib |
Unresolved |
4.0 |
23580575
|